News related to Tarceva (Erlotinib) and/or conditions it is approved for
FDA Approves Companion Genetic Diagnostic Test for Tarceva
Source: Medscape Today Headlines [2013.05.14]
The FDA has approved the first companion diagnostic test that can detect EGFR mutations in non-small cell lung cancer.
FDA OKs Test for Use with Tarceva
Source: MedPage Today Oncology/Hematology [2013.05.14]
WASHINGTON (MedPage Today) -- The FDA has approved a companion EGFR mutation test for use with the targeted cancer drug erlotinib (Tarceva) to help guide decision making in non-small cell lung cancer.
FDA Approves New Lung Cancer Diagnostic "Cobas EGFR Mutation Test"
Source: Cancer / Oncology News From Medical News Today [2013.05.15]
The U.S. Food and Drug Administration (FDA) has approved the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10 percent of non-small cell lung cancers (NSCLC)...